We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Read MoreHide Full Article
Travere Therapeutics (TVTX - Free Report) shares soared 26.2% in the last trading session to close at $27.31. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.3% gain over the past four weeks.
Travere’s stock surged after the FDA said no advisory committee review is needed for its Filspari supplemental new drug application in focal segmental glomerulosclerosis, with a decision due in January 2026. If approved, Filspari would become the first treatment specifically for the rare kidney disease, supported by strong clinical data showing significant proteinuria reduction and lower kidney failure risk. Already approved for IgA nephropathy, the drug recently gained a streamlined safety program, further boosting its potential adoption.
This drug developer is expected to post quarterly loss of $0.32 per share in its upcoming report, which represents a year-over-year change of +54.3%. Revenues are expected to be $102.15 million, up 62.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Travere, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on TVTX going forward to see if this recent jump can turn into more strength down the road.
Travere belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Regeneron (REGN - Free Report) , closed the last trading session 0.1% lower at $555.83. Over the past month, REGN has returned %.
For Regeneron, the consensus EPS estimate for the upcoming report has changed -0.8% over the past month to $9.46. This represents a change of -24.1% from what the company reported a year ago. Regeneron currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Travere Therapeutics (TVTX - Free Report) shares soared 26.2% in the last trading session to close at $27.31. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.3% gain over the past four weeks.
Travere’s stock surged after the FDA said no advisory committee review is needed for its Filspari supplemental new drug application in focal segmental glomerulosclerosis, with a decision due in January 2026. If approved, Filspari would become the first treatment specifically for the rare kidney disease, supported by strong clinical data showing significant proteinuria reduction and lower kidney failure risk. Already approved for IgA nephropathy, the drug recently gained a streamlined safety program, further boosting its potential adoption.
This drug developer is expected to post quarterly loss of $0.32 per share in its upcoming report, which represents a year-over-year change of +54.3%. Revenues are expected to be $102.15 million, up 62.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Travere, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on TVTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Travere belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Regeneron (REGN - Free Report) , closed the last trading session 0.1% lower at $555.83. Over the past month, REGN has returned %.
For Regeneron, the consensus EPS estimate for the upcoming report has changed -0.8% over the past month to $9.46. This represents a change of -24.1% from what the company reported a year ago. Regeneron currently has a Zacks Rank of #3 (Hold).